A Phase 3 interventional study of GSK548470 300 mg tablet in Hepatitis B, Chronic, sponsored by GlaxoSmithKline. Completed at 11 sites in Japan. Open to participants aged 16 Years to 69 Years. Per ClinicalTrials.gov, last updated 2015-06-22.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies testing tenofovir in Hepatitis B, Chronic — none open to participants now, 1 under way, 1 of them phase 3. Tenofovir · Hepatitis B, Chronic.
Among the 50 studies testing tenofovir in Hepatitis B, Chronic, this one is the 44th largest by enrollment, is one of 6 that started in 2011, is one of 13 in phase 3, and was the 20th registered.
896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.
Browse Hepatitis B, Chronic studies →None of the 50 studies testing tenofovir in Hepatitis B, Chronic is open now. The open studies under Hepatitis B, Chronic, anywhere →
Tenofovir: first FDA approval 2001 (VIREAD), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.
This study: 16 Years to 69 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 5 · Phase 3 13 · Phase 4 22
First in 2004; this study’s year is marked. 6 started in 2011.
This study's enrollment of 34 is below the median of 100 across 659 interventional studies indexed under Hepatitis B, Chronic.
Median enrollment 117 across the 50 interventional studies. Of the 37 that completed or were terminated, 17 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 50 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
30 studies in Hepatitis B, Chronic by GlaxoSmithKline: 1 open now, 2 under way, none of them phase 3. Of 28 finished, 18 (64%) have results posted.
Among the 30 studies in Hepatitis B, Chronic by GlaxoSmithKline, this one is the 27th largest by enrollment of the 28 interventional ones that give a count, is one of 5 that started in 2011, is one of 8 in phase 3, and was the 15th registered.
GlaxoSmithKline’s Hepatitis B, Chronic studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 50 studies testing tenofovir in Hepatitis B, Chronic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 30 in Hepatitis B, Chronic:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of once-daily treatment with GSK548470 300 mg in Japanese patients with compensated chronic hepatitis B with poor response to other drugs.
This is a multicenter, open-label study in Japanese patients with compensated chronic hepatitis B with poor response to other drugs in order to evaluate the efficacy and safety of GSK548470 administered at a dose of 300 mg once daily. The target sample size is set at 32 subjects. The primary objective is to evaluate the efficacy and safety of once-daily treatment with GSK548470 300 mg in subjects with compensated chronic hepatitis B with poor response to other drugs. The secondary objective is to evaluate the long-term efficacy and safety of once-daily treatment with GSK548470 300 mg.To evaluate the efficacy and safety of GSK548470 in the study, subjects receiving a combination of lamivudine (LAM) and adefovir pivoxil (ADV) will be switched to a combination of LAM and GSK548470, while subjects on entecavir hydrate (ETV) with or without ADV will be switched to a combination of ETV and GSK548470.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GSK548470 300 mg tablet is administered orally once daily
Drug: GSK548470 300 mg tablet
Blue tablets containing 300 mg of tenofovir disoproxil fumarate
Also known as: GSK548470
Number of Participants With HBV DNA Level < 2.1 log10 Copies/mL at Week 24
The number of participants with serum hepatitis B virus deoxyribonucleic acid (HBV DNA) level \< the lower limit of quantitation (2.1 log10 copies/millilitres\[copies/mL\]) (i.e., the rate of suppression) at Week 24 was summarized. Statistical analysis was not provided for the number of participants achieving HBV DNA \<2.1 log10 copies/mL (at Week 24). Missing values observed during the treatment period was imputed by the last observation carried forward (LOCF) method.
Time frame: Week 24
Mean Change From Baseline in Serum HBV DNA Level at Week 24, Week 48 and Week 96
The mean change from Baseline in the hepatitis B virus deoxyribonucleic acid (HBV DNA) level at Week 24, Week 48 and Week 96 were assessed (HBV DNA values below the lower limit of quantitation \[i.e. 2.1 log10 copies/mL\] for the assay were set to the lower limit minus 0.1 \[i.e. 2.0 log10 copies/mL\]). Change from Baseline was calculated as the post-Baseline value minus the Baseline value. The Last Observation Carried Forward (LOCF) method was applied for missing values.
Time frame: Baseline and Week 24, Week 48 and Week 96
Number of Participants With Serum HBV DNA < 2.1 log10 Copies/mL at Week 48 and Week 96
The number of participants with serum HBV DNA level \< the lower limit of quantitation (2.1 log10 copies/mL) (i.e., the rate of suppression) at Week 48 and Week 96 were summarized. The LOCF method was applied for missing values.
Time frame: Week 48 and Week 96
Number of Participants With Alanine Aminotransferase (ALT) Normalization at Week 24, Week 48 and Week 96
The number of participants with alanine aminotransferase (ALT) normalization at Week 24, Week 48 and Week 96 were summarized. ALT normalization is defined as when an ALT value exceeds the upper limit of normal range (ULN) at Baseline and within the normal range at the end of treatment. The LOCF method was applied for missing values.
Time frame: Week 24, Week 48 and Week 96
Number of Participants With HBeAg Loss at Week 24, Week 48 and Week 96
The number of participants achieving hepatitis Be antigen (HBeAg) loss at Week 24, Week 48 and Week 96 in positive HBeAg participants at Baseline were summarized. Loss of HBeAg is defined as the change of detectable HBeAg from positive to negative. The LOCF method was applied for missing values.
Time frame: Week 24, Week 48 and Week 96
Number of Participants With HBeAg/HBeAb Seroconversion at Week 24, Week 48 and Week 96
The number of participants achieving hepatitis Be antigen (HBeAg)/hepatitis B e antibody (HBeAb) seroconversion at Week 24, Week 48 and Week 96 in positive HBeAg and negative HBeAb participants at Baseline were summarized. Seroconversion to HBeAg is defined as change of detectable antibody to HBeAg from negative to positive. The LOCF method was applied for missing values.
Time frame: Week 24, Week 48 and Week 96
Number of Participants Achieving HBsAg Loss at Week 24, Week 48 and Week 96
The number of participants with hepatitis B surface antigen (HBsAg) loss at Week 24, Week 48 and Week 96 in positive HBsAg participants at Baseline were summarized. Loss of HBsAg is defined as change of detectable HBsAg from positive to negative. The LOCF method was applied for missing values.
Time frame: Week 24, Week 48 and Week 96
Number of Participants Achieving HBsAg/HBsAb Seroconversion at Week 24, Week 48 and Week 96
The number of participants with hepatitis B surface antigen (HBsAg)/hepatitis B surface antibody (HBsAb) seroconversion at Week 24, Week 48 and Week 96 in positive HBsAg and negative HBsAb participants at Baseline were summarized. HBsAg seroconversion was defined as change of detectable antibody to HBsAg from negative to positive. The LOCF method was applied for missing values.
Time frame: Week 24, Week 48 and Week 96
Number of Participants With Virological Breakthrough and Resistance-related Mutations
The number of participants who harbored resistance-related mutations and developed virological breakthrough was summarized. Virological breakthrough defined as HBV DNA level increase \>=1 log10 copies/mL above the treatment nadir were analyzed through end of treatment. Subjects who achieved the HBV-DNA values below lower limit of quantification (LLQ) (\< 2.1 log10 copies/mL) in quantitative analysis at Week 96 were also considered "negative" in drug-resistance without implementation of genotypic analysis. Lamivudine (LAM), adefovir pivoxil (ADV), and entecavir hydrate (ETV) resistance-related mutations were analyzed at Screening (i.e. Baseline), Week 24, Week 48 and Week 96 in participants with HBV DNA level above the lower limit of detection. Virologic breakthrough was defined as 1.0 log10 or greater increases in serum HBV DNA levels from on-treatment nadir. The LOCF method was applied for missing values.
Time frame: Screening, Week 24, Week 48, Week 96 and Virological Breakthrough
Number of Participants Achieving Each Indicated HBsAg Category at Baseline, Week 24, Week 48 and Week 96
The number of participants achieving each indicated hepatitis B surface antigen (HBsAg) category (HBsAg \<80, 80 to 800, 800 to 8000, 8000 to 80000, \>=80000) (kilo international unit per liter \[KIU/L\]) by study visit was summarized.
Time frame: Baseline, Week 24, Week 48 and Week 96
Number of Participants Achieving Each Indicated HBcrAg Category at Baseline,Week 24, Week 48 and Week 96
The number of participants achieving each indicated hepatitis B core-related antigen (HBcrAg) category (HBcrAg \<3.0 log10, 3.0 to 4.0 log10, 4.0 to 5.0 log10, 5.0 to 6.0 log10, \>=6.0 log10) (kilo units per liter \[KU/L\]) by study visit was summarized. The LOCF method was applied for missing values.
Time frame: Baseline, Week 24, Week 48 and Week 96
| Milestone | LAM 100 mg/TDF 300 mg | ETV 0.5 mg/TDF 300 mg |
|---|---|---|
| Started | 13 | 21 |
| Completed | 12 | 21 |
| Not completed | 1 | 0 |
| Withdrew: Protocol defined stopping criteria | 1 | 0 |
The number of participants with serum hepatitis B virus deoxyribonucleic acid (HBV DNA) level \< the lower limit of quantitation (2.1 log10 copies/millilitres\[copies/mL\]) (i.e., the rate of suppression) at Week 24 was summarized. Statistical analysis was not provided for the number of participants achieving HBV DNA \<2.1 log10 copies/mL (at Week 24). Missing values observed during the treatment period was imputed by the last observation carried forward (LOCF) method.
| participants | LAM 100 mg/TDF 300 mg | ETV 0.5 mg/TDF 300 mg |
|---|---|---|
| Number of Participants With HBV DNA Level < 2.1 log10 Copies/mL at Week 24 | 8 | 12 |
The mean change from Baseline in the hepatitis B virus deoxyribonucleic acid (HBV DNA) level at Week 24, Week 48 and Week 96 were assessed (HBV DNA values below the lower limit of quantitation \[i.e. 2.1 log10 copies/mL\] for the assay were set to the lower limit minus 0.1 \[i.e. 2.0 log10 copies/mL\]). Change from Baseline was calculated as the post-Baseline value minus the Baseline value. The Last Observation Carried Forward (LOCF) method was applied for missing values.
| log10 copies/mL | LAM 100 mg/TDF 300 mg | ETV 0.5 mg/TDF 300 mg |
|---|---|---|
| Week 24 | -2.72 (-3.50 to -1.93) | -3.33 (-4.01 to -2.65) |
| Week 48 | -2.88 (-3.70 to -2.06) | -3.50 (-4.28 to -2.73) |
| Week 96 | -3.02 (-3.84 to -2.21) | -3.50 (-4.35 to -2.66) |
The number of participants with serum HBV DNA level \< the lower limit of quantitation (2.1 log10 copies/mL) (i.e., the rate of suppression) at Week 48 and Week 96 were summarized. The LOCF method was applied for missing values.
| participants | LAM 100 mg/TDF 300 mg | ETV 0.5 mg/TDF 300 mg |
|---|---|---|
| Week 48 | 9 | 12 |
| Week 96 | 10 | 14 |
The number of participants with alanine aminotransferase (ALT) normalization at Week 24, Week 48 and Week 96 were summarized. ALT normalization is defined as when an ALT value exceeds the upper limit of normal range (ULN) at Baseline and within the normal range at the end of treatment. The LOCF method was applied for missing values.
| participants | LAM 100 mg/TDF 300 mg | ETV 0.5 mg/TDF 300 mg |
|---|---|---|
| Week 24 | 3 | 6 |
| Week 48 | 3 | 5 |
| Week 96 | 3 | 6 |
The number of participants achieving hepatitis Be antigen (HBeAg) loss at Week 24, Week 48 and Week 96 in positive HBeAg participants at Baseline were summarized. Loss of HBeAg is defined as the change of detectable HBeAg from positive to negative. The LOCF method was applied for missing values.
| participants | LAM 100 mg/TDF 300 mg | ETV 0.5 mg/TDF 300 mg |
|---|---|---|
| Week 24 | 0 | 0 |
| Week 48 | 1 | 0 |
| Week 96 | 1 | 0 |
The number of participants achieving hepatitis Be antigen (HBeAg)/hepatitis B e antibody (HBeAb) seroconversion at Week 24, Week 48 and Week 96 in positive HBeAg and negative HBeAb participants at Baseline were summarized. Seroconversion to HBeAg is defined as change of detectable antibody to HBeAg from negative to positive. The LOCF method was applied for missing values.
| participants | LAM 100 mg/TDF 300 mg | ETV 0.5 mg/TDF 300 mg |
|---|---|---|
| Week 24 | 0 | 0 |
| Week 48 | 0 | 0 |
| Week 96 | 0 | 0 |
The number of participants with hepatitis B surface antigen (HBsAg) loss at Week 24, Week 48 and Week 96 in positive HBsAg participants at Baseline were summarized. Loss of HBsAg is defined as change of detectable HBsAg from positive to negative. The LOCF method was applied for missing values.
| participants | LAM 100 mg/TDF 300 mg | ETV 0.5 mg/TDF 300 mg |
|---|---|---|
| Week 24 | 0 | 0 |
| Week 48 | 0 | 0 |
| Week 96 | 0 | 0 |
The number of participants with hepatitis B surface antigen (HBsAg)/hepatitis B surface antibody (HBsAb) seroconversion at Week 24, Week 48 and Week 96 in positive HBsAg and negative HBsAb participants at Baseline were summarized. HBsAg seroconversion was defined as change of detectable antibody to HBsAg from negative to positive. The LOCF method was applied for missing values.
| participants | LAM 100 mg/TDF 300 mg | ETV 0.5 mg/TDF 300 mg |
|---|---|---|
| Week 24 | 0 | 0 |
| Week 48 | 0 | 0 |
| Week 96 | 0 | 0 |
The number of participants who harbored resistance-related mutations and developed virological breakthrough was summarized. Virological breakthrough defined as HBV DNA level increase \>=1 log10 copies/mL above the treatment nadir were analyzed through end of treatment. Subjects who achieved the HBV-DNA values below lower limit of quantification (LLQ) (\< 2.1 log10 copies/mL) in quantitative analysis at Week 96 were also considered "negative" in drug-resistance without implementation of genotypic analysis. Lamivudine (LAM), adefovir pivoxil (ADV), and entecavir hydrate (ETV) resistance-related mutations were analyzed at Screening (i.e. Baseline), Week 24, Week 48 and Week 96 in participants with HBV DNA level above the lower limit of detection. Virologic breakthrough was defined as 1.0 log10 or greater increases in serum HBV DNA levels from on-treatment nadir. The LOCF method was applied for missing values.
| participants | LAM 100 mg/TDF 300 mg | ETV 0.5 mg/TDF 300 mg |
|---|---|---|
| Virological breakthrough, through end of study n=0 | 0 | 1 |
| LAM resistance-related mutations,Screening,n=13,21 | 11 | 17 |
| ADV resistance-related mutations,Screening,n=13,21 | 4 | 0 |
| ETV resistance-related mutations,Screening,n=13,21 | 6 | 16 |
| LAM resistance-related mutations, Week 24, n=5, 9 | 4 | 8 |
| ADV resistance-related mutations, Week 24, n=5, 9 | 2 | 0 |
| ETV resistance-related mutations, Week 24, n=5, 9 | 1 | 8 |
| LAM resistance-related mutations, Week 48, n= 3, 9 | 2 | 7 |
| ADV resistance-related mutations, Week 48, n= 3, 9 | 1 | 0 |
| ETV resistance-related mutations, Week 48, n= 3, 9 | 1 | 7 |
| LAM resistance-related mutations, Week 96, n= 2, 7 | 2 | 6 |
| ADV resistance-related mutations, Week 96, n= 2, 7 | 1 | 0 |
| ETV resistance-related mutations, Week 96, n= 2, 7 | 2 | 6 |
| LAM resistance-related mutations, VB, n=0,1 | 0 | 1 |
| ADV resistance-related mutations, VB, n=0,1 | 0 | 0 |
| ETV resistance-related mutations, VB, n=0,1 | 0 | 1 |
The number of participants achieving each indicated hepatitis B surface antigen (HBsAg) category (HBsAg \<80, 80 to 800, 800 to 8000, 8000 to 80000, \>=80000) (kilo international unit per liter \[KIU/L\]) by study visit was summarized.
| participants | LAM 100 mg/TDF 300 mg | ETV 0.5 mg/TDF 300 mg |
|---|---|---|
| HBsAg <80 KIU/L, Baseline | 0 | 0 |
| HBsAg 80-800 KIU/L, Baseline | 1 | 0 |
| HBsAg 800-8000 KIU/L, Baseline | 6 | 12 |
| HBsAg 8000-80,000 KIU/L, Baseline | 6 | 8 |
| HBsAg >=80,000 KIU/L, Baseline | 0 | 1 |
| HBsAg <80 KIU/L, Week 24 | 0 | 0 |
| HBsAg 80-800 KIU/L, Week 24 | 3 | 0 |
| HBsAg 800-8000 KIU/L, Week 24 | 5 | 15 |
| HBsAg 8000-80,000 KIU/L, Week 24 | 5 | 6 |
| HBsAg >=80,000 KIU/L, Week 24 | 0 | 0 |
| HBsAg <80 KIU/L, Week 48 | 0 | 0 |
| HBsAg 80-800 KIU/L, Week 48 | 3 | 1 |
| HBsAg 800-8000 KIU/L, Week 48 | 5 | 14 |
| HBsAg 8000-80,000 KIU/L, Week 48 | 5 | 6 |
| HBsAg >=80,000 KIU/L, Week 48 | 0 | 0 |
| HBsAg <80 KIU/L, Week 96 | 0 | 0 |
| HBsAg 80-800 KIU/L, Week 96 | 4 | 3 |
| HBsAg 800-8000 KIU/L, Week 96 | 6 | 13 |
| HBsAg 8000-80,000 KIU/L, Week 96 | 3 | 5 |
| HBsAg >=80,000 KIU/L, Week 96 | 0 | 0 |
The number of participants achieving each indicated hepatitis B core-related antigen (HBcrAg) category (HBcrAg \<3.0 log10, 3.0 to 4.0 log10, 4.0 to 5.0 log10, 5.0 to 6.0 log10, \>=6.0 log10) (kilo units per liter \[KU/L\]) by study visit was summarized. The LOCF method was applied for missing values.
| Participants | LAM 100 mg/TDF 300 mg | ETV 0.5 mg/TDF 300 mg |
|---|---|---|
| HBcrAg <3.0 Log KU/L, Baseline | 0 | 0 |
| HBcrAg 3.0-4.0 Log KU/L, Baseline | 0 | 1 |
| HBcrAg 4.0-5.0 Log KU/L, Baseline | 0 | 1 |
| HBcrAg 5.0-6.0 Log KU/L, Baseline | 1 | 0 |
| HBcrAg >=6.0 Log KU/L, Baseline | 12 | 19 |
| HBcrAg <3.0 Log KU/L, Week 24 | 0 | 0 |
| HBcrAg 3.0-4.0 Log KU/L, Week 24 | 0 | 1 |
| HBcrAg 4.0-5.0 Log KU/L, Week 24 | 1 | 1 |
| HBcrAg 5.0-6.0 Log KU/L, Week 24 | 1 | 1 |
| HBcrAg >=6.0 Log KU/L, Week 24 | 11 | 18 |
| HBcrAg <3.0 Log KU/L, Week 48 | 0 | 0 |
| HBcrAg 3.0-4.0 Log KU/L, Week 48 | 1 | 1 |
| HBcrAg 4.0-5.0 Log KU/L, Week 48 | 0 | 1 |
| HBcrAg 5.0-6.0 Log KU/L, Week 48 | 2 | 1 |
| HBcrAg >=6.0 Log KU/L, Week 48 | 10 | 18 |
| HBcrAg <3.0 Log KU/L, Week 96 | 0 | 0 |
| HBcrAg 3.0-4.0 Log KU/L, Week 96 | 1 | 1 |
| HBcrAg 4.0-5.0 Log KU/L, Week 96 | 0 | 1 |
| HBcrAg 5.0-6.0 Log KU/L, Week 96 | 3 | 2 |
| HBcrAg >=6.0 Log KU/L, Week 96 | 9 | 17 |
Collected over Serious adverse events (SAEs) and non-serious AEs were collected from the start of study medication to the end of the treatment period (up to average of 96 weeks).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| LAM 100 mg/TDF 300 mg | — | 1/13 (7.7%) | 12/13 (92.3%) |
| ETV 0.5 mg/TDF 300 mg | — | 2/21 (9.5%) | 17/21 (81%) |
| Event | LAM 100 mg/TDF 300 mg | ETV 0.5 mg/TDF 300 mg |
|---|---|---|
| Lumbar spinal stenosisMusculoskeletal and connective tissue disorders | 1/13 | 0/21 |
| Calculus uretericRenal and urinary disorders | 0/13 | 1/21 |
| AppendicitisInfections and infestations | 0/13 | 1/21 |
| Event | LAM 100 mg/TDF 300 mg | ETV 0.5 mg/TDF 300 mg |
|---|---|---|
| NasopharyngitisInfections and infestations | 7/13 | 11/21 |
| HeadacheNervous system disorders | 2/13 | 2/21 |
| Gallbladder polypHepatobiliary disorders | 2/13 | 0/21 |
| DiarrhoeaGastrointestinal disorders | 0/13 | 3/21 |
| RashSkin and subcutaneous tissue disorders | 1/13 | 3/21 |
| Alanine aminotransferase increasedInvestigations | 1/13 | 3/21 |
| Hepatic steatosisHepatobiliary disorders | 1/13 | 3/21 |
| DyspepsiaGastrointestinal disorders | 1/13 | 2/21 |
| Abdominal discomfortGastrointestinal disorders | 0/13 | 2/21 |
| Abdominal painGastrointestinal disorders | 0/13 | 2/21 |
| Age, Continuous(Years) | LAM 100 mg/TDF 300 mg | ETV 0.5 mg/TDF 300 mg | Total |
|---|---|---|---|
| Mean | 52.1 ± 7.57 | 50.3 ± 9.18 | 51.0 ± 8.52 |
| Sex: Female, Male(Participants) | LAM 100 mg/TDF 300 mg | ETV 0.5 mg/TDF 300 mg | Total |
|---|---|---|---|
| Female | 5 | 4 | 9 |
| Male | 8 | 17 | 25 |
| Race/Ethnicity, Customized(Participants) | LAM 100 mg/TDF 300 mg | ETV 0.5 mg/TDF 300 mg | Total |
|---|---|---|---|
| Asian-Japanese Heritage | 13 | 21 | 34 |
The record gives a start of Dec 2011, a primary completion of Jun 2013 and a completion of Oct 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2013, 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tenofovir